Medicofarma Biotech SA (WSE:MDB)
Poland flag Poland · Delayed Price · Currency is PLN
0.3090
-0.0010 (-0.32%)
At close: Aug 14, 2025

Medicofarma Biotech Cash Flow Statement

Millions PLN. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 20202016 - 2020
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2016 - 2020
Net Income
-3.21-2.3-3.44-1.59-0.22-0.92
Upgrade
Depreciation & Amortization
2.032.032.081.750.950.04
Upgrade
Loss (Gain) From Sale of Assets
-----0.070.13
Upgrade
Other Operating Activities
-0.33-0.330.790.050.01-
Upgrade
Change in Accounts Receivable
-0.25-0.250.20.86-1.290.49
Upgrade
Change in Inventory
000.140.41-0.420.21
Upgrade
Change in Other Net Operating Assets
0.24-0.160.23-0.512.84-0.26
Upgrade
Operating Cash Flow
-1.52-1.020.010.961.82-0.31
Upgrade
Operating Cash Flow Growth
---99.25%-47.11%--
Upgrade
Capital Expenditures
---1.11-1.21-2.3-
Upgrade
Sale of Property, Plant & Equipment
-----0
Upgrade
Sale (Purchase) of Real Estate
-----0.24
Upgrade
Other Investing Activities
-----13.71-
Upgrade
Investing Cash Flow
---1.11-1.21-16.010.34
Upgrade
Short-Term Debt Issued
-----0.23
Upgrade
Long-Term Debt Issued
-1.371.110.69--
Upgrade
Total Debt Issued
1.511.371.110.69-0.23
Upgrade
Long-Term Debt Repaid
--0.35-0.51--0.39-
Upgrade
Net Debt Issued (Repaid)
1.511.020.60.69-0.390.23
Upgrade
Issuance of Common Stock
----14.65-
Upgrade
Other Financing Activities
----0.01-0.01-0.3
Upgrade
Financing Cash Flow
1.511.020.60.6814.25-0.07
Upgrade
Net Cash Flow
-0.010-0.50.430.05-0.04
Upgrade
Free Cash Flow
-1.52-1.02-1.1-0.25-0.48-0.31
Upgrade
Free Cash Flow Margin
-543.42%-83.23%-146.38%-5.83%-14.48%-8.54%
Upgrade
Free Cash Flow Per Share
-0.02-0.01-0.02-0.00-0.01-0.05
Upgrade
Cash Interest Paid
----0.010.02
Upgrade
Levered Free Cash Flow
-0.17-0.54-0.790.99-1.370.2
Upgrade
Unlevered Free Cash Flow
-0.02-0.39-0.681-1.360.21
Upgrade
Change in Working Capital
-0-0.410.570.761.130.43
Upgrade
Updated Feb 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.